Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 13/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233529 | 0.83 | NPY5R (0.54) | NPY5RSIGMAR1HRH3DRD4DRD3 | |
| SCHEMBL4236883 | 0.81 | SIGMAR1 (0.55) | NPY5RCACNA1BSIGMAR1HRH3CACNA1C | |
| SCHEMBL4229226 | 0.81 | SIGMAR1 (0.56) | NPY5RSIGMAR1HRH3CACNA1FDRD1 | |
| SCHEMBL4226623 | 0.77 | NPY5R (0.55) | NPY5RSIGMAR1HRH3 | |
| SCHEMBL4386075 | 0.77 | CACNA1B (0.66) | CACNA1BCACNA1FDRD1DRD4DRD5 | |
| SCHEMBL4236679 | 0.77 | SIGMAR1 (0.54) | CACNA1BSIGMAR1CACNA1FDRD1DRD4 | |
| SCHEMBL3860397 | 0.76 | SIGMAR1 (0.60) | NPY5RSIGMAR1HRH3 | |
| SCHEMBL4223179 | 0.76 | CACNA1B (0.53) | CACNA1BCACNA1FDRD1DRD4DRD5 | |
| SCHEMBL3850632 | 0.75 | NPY5R (0.52) | NPY5RSIGMAR1HRH3 | |
| SCHEMBL26330800 | 0.75 | CACNA1B (0.52) | CACNA1BSIGMAR1HRH3CACNA1FDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | claimed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | claimed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8546417-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546417-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546417-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
| EP-1943250-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007028638-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028638-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | NPY5R 683/4885CACNA1B 4/4885SIGMAR1 220/4885 |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | NPY5R 683/4885CACNA1B 4/4885SIGMAR1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.